Journal article
Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
Abstract
BACKGROUND: The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 mg BID was noninferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. In this subgroup analysis, we assess the efficacy and safety of dabigatran in patients who did and did not receive concomitant antiplatelets.
METHODS AND …
Authors
Dans AL; Connolly SJ; Wallentin L; Yang S; Nakamya J; Brueckmann M; Ezekowitz M; Oldgren J; Eikelboom JW; Reilly PA
Journal
Circulation, Vol. 127, No. 5, pp. 634–640
Publisher
Wolters Kluwer
Publication Date
February 5, 2013
DOI
10.1161/circulationaha.112.115386
ISSN
0009-7322